PriceSensitive

Titan Medical (TSX:TMD) commences strategic review process

Health Care, Market News
TSX:TMD
30 November 2022 09:15 (EDT)

Titan Medical's surgeon workstation

Titan Medical (TMD) has begun a strategic review process to unlock shareholder value.

The company’s Board of Directors, in consultation with its financial and legal advisors, decided that it is in the best interest of the company and its stakeholders to undertake a review and evaluation of strategic alternatives that may be available to the company.

To this end, the Board is open to considering a full range of strategic alternatives, including a corporate sale, merger or other business combination, a sale of all or a portion of the company’s assets, strategic investment or other significant transaction.

Consequently, the company has engaged Raymond James as a financial advisor to advise the company in connection with this broad and comprehensive review and analysis of strategic alternatives.

“Our management team is completely aligned with the Board’s decision to explore options to maximize shareholder value,” said Cary G. Vance, Titan’s President and CEO.

“We believe it is prudent to undertake a review of our strategic options to determine the best path forward to realize the value of our innovations in single-access robotic-assisted technologies to maximize shareholder value,” he added.

The company has not set a timetable for the completion of the process. It does not intend to provide any updates on developments unless and until the company signs a definitive agreement or the Board otherwise determines that an update is appropriate or required.

Titan Medical Inc., a medical device company, headquartered in Toronto, Ontario and with operations in Chapel Hill, North Carolina, is focused on enhancing robotic-assisted surgery (RAS) using innovative technology through a single access point.

Titan Medical Inc. opened trading at $0.52 per share.


Related News